HAE — HAEMONETICS CORP

NYSE · Health Care · Health Care Equipment & Supplies · CIK 313143 ·
Last close
$76.91
Market Cap
$3.50B
52W High
$81.99
52W Low
$51.00
ADV30
1,054,930
Next earnings
2026-08-06
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 346,351,000 198,212,000 52,342,000 -20,147,000 2,395,925,000 245,440,000 1,599,605,000
Dec 2025 338,967,000 202,386,000 68,112,000 44,740,000 2,490,890,000 363,367,000 1,579,439,000
Sep 2025 327,315,000 194,744,000 67,075,000 38,684,000 2,442,156,000 296,426,000 1,592,983,000
Jun 2025 321,394,000 192,244,000 53,872,000 34,031,000 2,462,094,000 292,898,000 1,579,794,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$293,221,000
Investing CF
$-179,547,000
Financing CF
$-178,460,000
CapEx
$-32,780,000
Dividends Paid
Buybacks
$-250,000,000
EPS Diluted TTM
$3.63
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$279,344,000
Inventory
$306,370,000
Receivables
$216,855,000
ST Investments
EBIT TTM
$156,734,000
Pretax Income TTM
$128,030,000
Interest Exp TTM
$28,704,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,334,027,008
EBITDA
$357,151,008
Free Cash Flow
$298,094,240
Enterprise Value
$4,523,708,416
Total Cash
$246,263,008
Total Debt
$1,274,721,024
Shares Out
45,445,983
Trailing EPS
$2.05
Book Value
$17.60
ROE
12.0%
ROA
6.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 1,334,027,000 241,401,000 97,308,000 2,395,925,000 1,599,605,000 293,221,000
Mar 2025 1,360,824,000 201,186,000 167,679,000 2,450,948,000 1,630,112,000 181,725,000
Mar 2024 1,309,055,000 173,302,000 117,558,000 2,195,591,000 1,235,632,000 181,751,000
Mar 2023 1,168,660,000 155,651,000 115,401,000 1,934,825,000 1,116,828,000 273,058,000

TTM Snapshot

Revenues TTM
$1,249,862,000
NetIncome TTM
$124,911,000
OpCashFlow TTM
$0
Assets (Latest)
$2,450,948,000
Forward EPS
$5.76

Max Pain — expiry 2026-07-17

max pain strike: $70.00 · spot: $74.26 · call oi: 2,069 · put oi: 1,022
Expected Move to 2026-07-17: ±$7.05 (9.49%) — implied range $67.21$81.31 · ATM straddle on $75.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ICUI ICU MEDICAL INC/DE $3.59B $143.72
IRTC iRhythm Holdings, Inc. $3.74B $113.76
ITGR Integer Holdings Corp $3.08B $90.85
MMSI MERIT MEDICAL SYSTEMS INC $3.99B $66.94
NVST Envista Holdings Corp $4.02B $24.68

News headlines (Yahoo Finance, 1h cache)

A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
2026-06-09 16:10 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-05 19:49 · Yahoo
Haemonetics Updates Financial Reporting Segments
2026-06-05 10:30 · Yahoo
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-02 20:05 · Yahoo
John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson
2026-05-28 13:38 · Yahoo
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next
2026-05-25 13:14 · Yahoo
Haemonetics (HAE) Stock Is Up, What You Need To Know
2026-05-23 21:16 · Yahoo
Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)
2026-05-23 01:48 · Yahoo
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
2026-05-22 13:15 · Yahoo
Does Haemonetics (HAE) Have Enduring Growth Potential?
2026-05-21 14:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.